Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation

Table 2

Baseline characteristics of the included studies.

Published year	First author	Study design	No. of patients	Inclusion criteria in tumor size and tumor number	Child-Pugh class	Interval of follow-up	Age, years, median (range), or mean ± SD
2011	Yun	Retro	170	Single tumor ≤3 cm	Child A5	3 months	57.0 ± 9.9
2013	Kang	Retro	183	Single tumor ≤3 cm	Child A/B	3 months	57.2 ± 9.4
2015	Kang	Retro	438	Single tumor ≤3 cm	Child A/B	3 months	58 (30–80)
2018	Lee	Retro	62	Single tumor ≤3 cm	Child A/B	3 months	56.0 ± 9.7
2019	Doyle	Retro	167	Single tumor ≤2 cm	Child A/B	3 months	57.6 ± 6.0
2020	Yun	Retro	122	Milan criteria	Child A/B	3 months	69.1 ± 10.1
2010	Huang	RCT	115	Milan criteria	Child A/B	3 months	54.7 ± 12.2
2017	Ng	RCT	109	Milan criteria	Child A/B	3 months	57 (23–78)
2012	Peng	RCT	70	Milan criteria (recurrence)	Child A/B	3-4 months	55.1 ± 9.5
2012	Lai	Retro	117	Single tumor ≤3 cm	Child A/B	2 months	54.9 ± 11.3
2004	Lin	RCT	52	Size ≤4 cm and number ≤3	Child A/B	2 months	62.0 ± 11.0
2006	Chen	RCT	71	Single tumor ≤5 cm	Child A	2 months	51.9 ± 11.2
2005	Lin	RCT	62	Size ≤3 cm and number ≤3	Child A/B	2-3 months	61.0 ± 10.0
2009	Shibata	RCT	43	Size ≤3 cm and number ≤3	Child A/B	2-3 months	69.8 ± 8.0
2017	Yun	Retro	159	Single tumor ≤2 cm	Child A/B	2-3 months	54.0 ± 11.0

RCT, randomized controlled trial; Retro, retrospective study.